Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients.
作者信息
Patel K, Gooley T A, Bailey N, Bailey M, Hegerova L, Batchelder A, Holdread H, Dunleavy V, Downey T, Frisvold J, Megrath S, Pagarigan K, Szeto J, Rueda J, Islam A, Maree C, Nyatsatsang S, Bork S E, Lipke A, O'Mahony D S, Wagner T, Pulido J, Mignone J, Youssef S, Hartman M, Goldman J D, Pagel J M
机构信息
From the Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
出版信息
J Intern Med. 2021 Mar;289(3):430-433. doi: 10.1111/joim.13163. Epub 2020 Oct 20.
Abstract
摘要
相似文献
1
Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients.在住院的COVID-19患者中使用白细胞介素-6受体拮抗剂托珠单抗。
J Intern Med. 2021 Mar;289(3):430-433. doi: 10.1111/joim.13163. Epub 2020 Oct 20.
2
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
3
Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.COVID-19 住院患者免疫调节前后的细胞因子谱。
J Clin Immunol. 2021 May;41(4):738-747. doi: 10.1007/s10875-020-00949-6. Epub 2021 Jan 18.
4
Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.托珠单抗与单独的标准治疗相比，可显著降低住院 COVID-19 患者的 C 反应蛋白水平。
Microbiol Spectr. 2024 Jun 4;12(6):e0249823. doi: 10.1128/spectrum.02498-23. Epub 2024 Apr 30.
5
Effects of Tocilizumab in COVID-19 patients: a cohort study.托珠单抗治疗 COVID-19 患者的效果：一项队列研究。
BMC Infect Dis. 2020 Dec 22;20(1):964. doi: 10.1186/s12879-020-05701-4.
6
COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab.COVID-19 急性呼吸窘迫综合征：托珠单抗联合西妥昔单抗联合治疗效果的模拟研究。
Br J Clin Pharmacol. 2022 Mar;88(3):1043-1053. doi: 10.1111/bcp.15009. Epub 2021 Sep 14.
7
Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.托珠单抗并未降低 COVID-19 住院患者的低氧性呼吸衰竭或死亡风险。
Ann Intern Med. 2021 Feb;174(2):JC16. doi: 10.7326/ACPJ202102160-016. Epub 2021 Feb 2.
8
Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis.托珠单抗在 COVID-19 患者中的剂量和给药策略：一项回顾性队列分析。
Ann Pharmacother. 2024 Apr;58(4):391-397. doi: 10.1177/10600280231190401. Epub 2023 Jul 31.
9
Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study.托珠单抗对 COVID-19 住院患者死亡率的影响：一项多中心队列研究。
Clin Microbiol Infect. 2021 Feb;27(2):238-243. doi: 10.1016/j.cmi.2020.09.021. Epub 2020 Sep 23.
10
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
引用本文的文献
1
Immunosuppressive and Non-Immunosuppressive Drugs for Heart Xenotransplantation in Humans: Is Europe Ready?用于人类心脏异种移植的免疫抑制和非免疫抑制药物：欧洲准备好了吗？
Xenotransplantation. 2025 Jul-Aug;32(4):e70061. doi: 10.1111/xen.70061.
2
Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury.免疫调节：对抗SARS-CoV-2诱导的心肌损伤的关键。
Front Immunol. 2025 May 14;16:1561946. doi: 10.3389/fimmu.2025.1561946. eCollection 2025.
3
MJDs family members: Potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.马查多-约瑟夫病（MJD）家族成员：肝细胞癌潜在的预后靶点及免疫相关生物标志物
Front Genet. 2022 Sep 9;13:965805. doi: 10.3389/fgene.2022.965805. eCollection 2022.
4
Upregulation of hsa_circ_0004812 promotes COVID-19 cytokine storm via hsa-miR-1287-5p/IL6R, RIG-I axis.环状 RNA hsa_circ_0004812 通过 hsa-miR-1287-5p/IL6R、RIG-I 轴上调促进 COVID-19 细胞因子风暴。
J Clin Lab Anal. 2022 Oct;36(10):e24666. doi: 10.1002/jcla.24666. Epub 2022 Aug 21.
5
Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis.托珠单抗对成人新型冠状病毒肺炎的影响：一项荟萃分析。
Front Med (Lausanne). 2022 Mar 30;9:838904. doi: 10.3389/fmed.2022.838904. eCollection 2022.
6
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.托珠单抗治疗 COVID-19 住院患者的疗效：系统评价和荟萃分析。
Respirology. 2021 Nov;26(11):1027-1040. doi: 10.1111/resp.14152. Epub 2021 Oct 3.
7
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.托珠单抗治疗重症 COVID-19 的获益和危害：系统评价和荟萃分析。
Pharmacotherapy. 2021 Nov;41(11):884-906. doi: 10.1002/phar.2627. Epub 2021 Oct 1.
8
Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.托珠单抗降低COVID-19患者死亡率的效果：一项系统评价与Meta分析
J Pers Med. 2021 Jul 1;11(7):628. doi: 10.3390/jpm11070628.
9
Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis.托珠单抗治疗新冠病毒肺炎患者的疗效与安全性：一项病例对照研究及荟萃分析
Infect Dis Ther. 2021 Sep;10(3):1677-1698. doi: 10.1007/s40121-021-00483-x. Epub 2021 Jul 9.
10
Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.白细胞介素 6（IL-6）抑制剂作为治疗 2019 冠状病毒病（COVID-19）的药物：系统评价和荟萃分析。
J Infect Public Health. 2021 Aug;14(8):1001-1009. doi: 10.1016/j.jiph.2021.06.004. Epub 2021 Jun 15.
本文引用的文献
1
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.西雅图地区危重症新冠患者-病例系列。
N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
2
Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.华盛顿州 21 例 COVID-19 危重症患者的特征和结局。
JAMA. 2020 Apr 28;323(16):1612-1614. doi: 10.1001/jama.2020.4326.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response.意大利伦巴第大区新冠疫情期间的重症监护利用情况：应急响应中的早期经验与预测
JAMA. 2020 Apr 28;323(16):1545-1546. doi: 10.1001/jama.2020.4031.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
6
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Zotero 插件